BioSpace News Archive

Heska Corporation announced that members of Heska’s management team will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Biostage, Inc. today announced the publication of a paper in the peer-reviewed Journal of Immunology and Regenerative Medicine that describes the early tissue growth and regeneration processes following the implantation of the Biostage Esophageal Implant (BEI) in nine pigs with full circumferential esophageal segmental replacement.

Outlook Therapeutics, Inc. announced that it has entered into a Securities Purchase Agreement (“SPA”) with an accredited investor (the “lender”), and pursuant to the SPA, issued the lender an unsecured convertible promissory note (the “Note”) with a face amount of $31,820,000.

Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) today announced that the company has terminated its liquidity guarantee agreement with Erik Penser Bank AB. The volumes in the share trading are deemed to be sufficient to ensure satisfactory liquidity even without a guarantee, and the termination gives the opportunity for more efficient cost allocation to benefit the company’s development projects.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today shared multiple accomplishments and advances in its research and development (R&D) programs.

Oragenics, Inc. announced that its Board of Directors on December 22, 2022 approved a 1-for-60 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the Company’s authorized shares of common stock, such that, following the consummation of the Reverse Stock Split, the number of authorized shares of common stock will be reduced from 250,000,000 shares to 4,166,666 shares.

Pyxis Oncology, Inc. reported on December 23, 2022 that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 52,560 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 65,701 shares of Pyxis Oncology’s common stock to five newly hired employees.

The U.S. Food and Drug Administration issued a Complete Response Letter regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation in people living with fibrodysplasia ossificans progressiva.

Ardelyx, Inc. announced that on December 16, 2022, the compensation committee of the company’s board of directors granted 17 new non-executive employees options to purchase an aggregate of 271,735 shares of the company’s common stock, and an aggregate of 123,375 Restricted Stock Units.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,250 shares of the Company’s common stock at an exercise price per share of $20.41, which was the closing price on December 23, 2022, and restricted stock units to acquire a total of 5,625 shares of the Company’s common stock.